Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 2/20 | 0.49 |
| ▸ | RXRG | P48443 | 2/20 | 0.49 |
| ▸ | RXRB | P28702 | 1/20 | 0.42 |
| ▸ | KIF11 | P52732 | 1/20 | 0.40 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.40 |
| ▸ | MRGPRX4 | Q96LA9 | 4/20 | 0.39 |
| ▸ | GRM5 | P41594 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | XDH | P47989 | 1/20 | 0.38 |
| ▸ | PRKCA | P17252 | 1/20 | 0.37 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.37 |
| ▸ | IDO1 | P14902 | 2/20 | 0.36 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.36 |
| ▸ | TMPRSS4 | Q9NRS4 | 1/20 | 0.35 |
| ▸ | CES2 | O00748 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17319636 | 0.83 | RXRA (0.47) | RXRARXRGKIF11TAS2R14MRGPRX4 | |
| SCHEMBL29812995 | 0.81 | RXRA (0.46) | RXRARXRGKIF11TAS2R14MRGPRX4 | |
| SCHEMBL2390020 | 0.81 | RXRA (0.49) | RXRARXRGKIF11TAS2R14MRGPRX4 | |
| SCHEMBL172834 | 0.81 | RXRA (0.46) | RXRARXRGKIF11TAS2R14MRGPRX4 | |
| SCHEMBL172532 | 0.81 | RXRA (0.46) | RXRARXRGKIF11TAS2R14MRGPRX4 | |
| SCHEMBL24108532 | 0.81 | RXRA (0.46) | RXRARXRGKIF11TAS2R14MRGPRX4 | |
| SCHEMBL169517 | 0.81 | RXRA (0.46) | RXRARXRGKIF11TAS2R14MRGPRX4 | |
| SCHEMBL130428 | 0.81 | RXRA (0.46) | RXRARXRGKIF11TAS2R14MRGPRX4 | |
| SCHEMBL3590487 | 0.80 | RXRA (0.59) | RXRARXRGRXRBKIF11PTGDR2 | |
| SCHEMBL29918281 | 0.80 | RXRA (0.43) | RXRARXRGRXRBKIF11TAS2R14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 72 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2900645-A1 | 3-PHENYLISOXAZOLIN DERIVATIVES WITH HERBICIDAL ACTION | Bayer CropScience AG (DE) | 2015-08-05 | — | — | EP | disclosed |
| EP-2149563-B9 | NOVEL PYRIMIDINE COMPOUND HAVING DIBENZYLAMINE STRUCTURE, AND MEDICINE COMPRISING THE COMPOUND | KOWA CO (JP) | 2015-04-22 | — | — | EP | disclosed |
| CN-103172562-B | Trisubstituted amine compounds as inhibitors of cholesteryl ester transfer protein CETP | TANABE SEIYAKU CO | 2015-04-22 | — | — | CN | disclosed |
| EP-2149563-B1 | NOVEL PYRIMIDINE COMPOUND HAVING DIBENZYLAMINE STRUCTURE, AND MEDICINE COMPRISING THE COMPOUND | KOWA CO (JP) | 2015-01-07 | — | — | EP | disclosed |
| CN-101374817-B | Trisubstituted amine compounds as inhibitors of cholesteryl ester transfer protein CETP | MITSUBISHI TANABE PHARMA CORP | 2014-07-30 | — | — | CN | disclosed |
| CN-103172562-A | Trisubstituted amine compounds as inhibitors of cholesteryl ester transfer protein CETP | TANABE SEIYAKU CO | 2013-06-26 | — | — | CN | disclosed |
| US-8383821-B2 | NK-1 and serotonin transporter inhibitors | BRISTOL-MEYERS SQUIBB COMPANY (US) | 2013-02-26 | — | — | US | disclosed |
| US-8383821-B2 | NK-1 and serotonin transporter inhibitors | BRISTOL-MEYERS SQUIBB COMPANY (US) | 2013-02-26 | — | — | US | disclosed |
| US-8383821-B2 | NK-1 and serotonin transporter inhibitors | BRISTOL-MEYERS SQUIBB COMPANY (US) | 2013-02-26 | — | — | US | disclosed |
| EP-2138489-B9 | NOVEL PYRIMIDINE COMPOUND HAVING BENZYL(HETEROCYCLICMETHYL)AMINE STRUCTURE AND PHARMACEUTICAL PRODUCT CONTAINING THE SAME | KOWA CO (JP) | 2012-10-24 | — | — | EP | disclosed |
| WO-2007088999-A1 | TRISUBSTITUTED AMINE COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2007-08-09 | — | — | WO | disclosed |
| WO-2007088996-A1 | TRISUBSTITUTED AMINE COMPOUNDS AS INHIBITORS OF -CHOLESTERYL ESTER TRANSFER PROTEIN CETP | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2007-08-09 | — | — | WO | disclosed |
| EP-1533292-B1 | DIBENZYLAMINE COMPOUND AND MEDICINAL USE THEREOF | JAPAN TOBACCO INC (JP) | 2007-02-14 | — | — | EP | disclosed |
| CN-1289467-C | Dibenzylamine compound and pharmaceutical use thereof | JAPAN TOBACCO INC (JP) | 2006-12-13 | — | — | CN | disclosed |
| JP-2006045095-A | 3-FORMYL-5-TRIFLUOROMETHYLBENZONITRILE DERIVATIVE AND METHOD FOR PRODUCING THE SAME | CENTRAL GLASS CO LTD | 2006-02-16 | — | — | JP | disclosed |
| JP-2005272324-A | 3-FORMYL-5-TRIFLUOROMETHYLBENZONITRILE DERIVATIVE AND ITS MANUFACTURING METHOD | CENTRAL GLASS CO LTD | 2005-10-06 | — | — | JP | disclosed |
| EP-1533292-A1 | DIBENZYLAMINE COMPOUND AND MEDICINAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2005-05-25 | — | — | EP | disclosed |
| CN-1617850-A | Dibenzylamine compound and medicinal use thereof | JAPAN TOBACCO INC (JP) | 2005-05-18 | — | — | CN | disclosed |
| US-20050059810-A1 | Dibenzylamine compound and medicinal use thereof | JAPAN TOBACCO INC | 2005-03-17 | — | — | US | disclosed |
| US-4835154-A | 1-aralykyl-5-piperazinylmethyl-2-mercaptoimidazoles and 2-alkylthioimidazoles and their use as dopamine-βhydroxylase inhibitors | SMITHKLINE BECKMAN CORPORATION (US) | 1989-05-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050059810-A1 | Dibenzylamine compound and medicinal use thereof | CETP, CES1, APOB | RXRA 2254/4885RXRG 2391/4885RXRB 1723/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.